Copyright
©The Author(s) 2017.
World J Gastrointest Endosc. Aug 16, 2017; 9(8): 359-367
Published online Aug 16, 2017. doi: 10.4253/wjge.v9.i8.359
Published online Aug 16, 2017. doi: 10.4253/wjge.v9.i8.359
Table 1 Colorectal cancer surveillance guidelines for inflammatory bowel disease patients
Guideline (year of publication) | Timing of initiating surveillance | Surveillance interval | Biopsy protocol |
AGA (2003)[4] | After 8 yr of disease (pancolitis) After 15 yr of disease (left-sided colitis) | 1-2 yr | Random biopsy |
BSG (2010)[46] | 10 yr after onset of colitic symptoms | 5 yr (lower risk)1 2-3 yr (intermediate risk) 1 yr (higher risk) | Targeted biopsy with CE (preferred) otherwise random biopsy |
ECCO (2013)[6] | 8 yr after onset of colitic symptoms | 5 yr (lower risk)2 2-3 yr (intermediate risk) 1 yr (higher risk) | Targeted biopsy with CE (preferred), random biopsies if CE expertise unavailable |
ASGE (2015)[7] | 8 yr after symptom onset | 1-3 yr (1 yr if any risk factor)3 | Targeted biopsy with CE recommended with SD-WLE (preferred with HD-WLE as well); random biopsies with targeted biopsies of suspicious lesions is alternative |
- Citation: Shukla R, Salem M, Hou JK. Use and barriers to chromoendoscopy for dysplasia surveillance in inflammatory bowel disease. World J Gastrointest Endosc 2017; 9(8): 359-367
- URL: https://www.wjgnet.com/1948-5190/full/v9/i8/359.htm
- DOI: https://dx.doi.org/10.4253/wjge.v9.i8.359